Arsenic trioxide (As 2 O 3 ) is an effective treatment for acute promyelocytic leukemia (APL), but is less effective against other leukemias. Although the response of APL cells to As 2 O 3 has been linked to degradation of the PML/RARa fusion oncoprotein, there is evidence that PML/RARa expression is not the only mediator of arsenic sensitivity. Indeed, we found that exogenous expression of PML/RARa did not sensitize a non-APL leukemic line to As 2 O 3 . To evaluate possible other determinants of sensitivity of leukemic cells to As 2 O 3 , we derived two arsenic-resistant NB4 subclones. Despite being approximately 10-fold more resistant to arsenic than their parental cell line, PML/RARa protein was still degraded by As 2 O 3 in these cells, providing further evidence that loss of expression of the oncoprotein does not confer arsenic sensitivity. Both arsenic-resistant clones contained high glutathione (GSH) levels, however, and we found that GSH depletion coupled with As 2 O 3 treatment dramatically inhibited their growth. Annexin V-staining and TUNEL analysis confirmed a synergistic induction of apoptosis. In addition, these cells failed to accumulate ROS in response to arsenic treatment, in contrast to their arsenic-sensitive parental cells, unless cotreated with buthionine sulfoximine. While other malignant cells did not show a good correlation between arsenic sensitivity and GSH content, GSH depletion nevertheless sensitized all cell lines examined, regardless of their initial response to arsenic alone. These findings suggest that PML/RARa expression is not a determinant of arsenic sensitivity, and further support the coupling of GSH depletion and arsenic treatment as a novel treatment for human malignancies that are unresponsive to arsenic alone. Leukemia (2003) 17, 931-940.
Introduction
Resistance to chemotherapy is a major problem in the management of cancer, where there is a clear need to search for more effective treatment strategies. Recently, arsenic trioxide (As 2 O 3 ) has been shown to induce remission in acute promyelocytic leukemia (APL) patients [1] [2] [3] resistant to conventional therapies. APL is a unique form of myeloid leukemia characterized by a reciprocal chromosomal translocation that fuses the PML gene on chromosome 15 with that encoding the retinoic acid receptor a (RARa) on chromosome 17. 4, 5 The PML/RARa fusion protein generated by this translocation retains most of the functional domains of the nuclear receptor, RARa, and acts as a dominant negative inhibitor of retinoid, and possibly PML, signalling. [5] [6] [7] The block to differentiation caused by the expression of this oncoprotein can be overcome, in vitro and in vivo, by treatment with retinoic acid (RA). 8, 9 Like RA, arsenic has been shown by our lab and others to induce downregulation of PML/RARa protein levels. 10, 11 In contrast to RA, however, As 2 O 3 induces apoptosis of affected promyelocytes, rather than terminal differentiation. 11, 12 To date, however, the clinical applications of arsenicals have been limited to the treatment of APL, which appears to be a uniquely sensitive target for therapy with this agent.
Research into the nature of arsenic sensitivity of APL cells has implicated glutathione (GSH) and GSH regulation in the response to arsenic. 13 GSH is a ubiquitously expressed tripeptide that serves as the largest source of nonprotein thiol groups within the cell. Among its important intracellular functions are the squelching of free radicals, detoxification of electrophilic compounds through glutathione S-transferase (GST)-mediated reactions, and maintenance of a normal redox state. A recent study suggested that the sensitivity of NB4 cells to arsenic was because of their low GSH content. Furthermore, some reports suggest that modulation of GSH, and GSH utilization pathways, including upregulation of glutathione-Stransferase p (GSTp) and the multidrug resistance-associated protein (MRP), can confer metal resistance. [13] [14] [15] [16] [17] [18] [19] [20] Owing to its known role as an environmental carcinogen, the question of how arsenic exerts its toxic effects has been the subject of intense study in recent years. In addition to causing mitochondrial toxicity, 21 impairing microtubule polymerization, 22 and deregulating a number of proteins and enzymes through sulfhydryl binding, 23 considerable evidence suggests that arsenic induces oxidative stress and the generation of hydrogen peroxide (H 2 O 2 ) and other reactive oxygen species (ROS). [24] [25] [26] [27] [28] For example, an H 2 O 2 -resistant Chinese hamster ovary (CHO) cell line displays crossresistance to arsenic, a catalase-deficient CHO cell line is hypersensitive to arsenic, and free radical scavengers such as DMSO can confer protection against arsenic-induced apoptosis. 29 Therefore, given the high sensitivity of APL cells to arsenic, we investigated the role of PML/RARa expression, as well as of GSH and ROS levels, as determinants of sensitivity in these and other, less sensitive AML cell lines.
Materials and methods

Cell culture
All cells were grown in a humidified chamber at 371C with a 5% CO 2 environment. NB4, (provided by Dr M Lanotte), NB4-MAsR2, NB4-M-AsR3, PLB-985, U937-SN4, and U937-PR9 cells (provided by Dr PG Pelicci) were cultured in RPMI 1640 media (Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD, USA) supplemented with 10% fetal calf serum (FCS). NB4-M-AsR2 and NB4-M-AsR3 cells were also maintained in the presence of 2 mM As 2 O 3 (Sigma, Oakville, Ontario, Canada).
Growth assays
NB4, PLB-985, and U937 cells were seeded at 2 Â 10 5 cells/ml in six-well plates. Cells were treated with various concentrations of As 2 O 3 (Sigma) for 7 days, which was refreshed at every third day. Viable cells were counted by trypan blue (Life Technologies) exclusion with a hemacytometer. NB4, PLB-985, and U937 cells were maintained at a density lower than 1 Â 10 6 cells/ml through dilution as required.
Induction and detection of PML/RARa expression U937 cells stably transfected with a zinc-inducible PML/RARa expression vector were seeded at 1 Â 10 3 cells/well in 96-well plates. Cells were treated with 100 mM Zn 2 SO 4 for 24 h prior to the addition of As 2 O 3 to induce expression of the fusion protein. Nuclear extracts were prepared by first washing 1 Â 10 7 cells twice with PBS and resuspending in 2 ml PTG buffer (5 mM NaH 2 PO 4 , 1 mM DTT, 10% glycerol, 1 mM PMSF, 10 mg/ml each aprotinin and leupeptin, pH 7.4) at 41C. Then cells were homogenized using a Dounce and pestle (pestle B) and the extracts transferred to centrifuge tubes. Following centrifugation for 30 min at 800 g at 41C, the nuclear pellet was washed with 1 ml PTG buffer and recentrifuged as above. Nuclear pellets were suspended in ice-cold TTGK buffer (10 mM Tris-Cl, pH 8.5, 1 mM EDTA, 1 mM DTT, 10% glycerol, 0.8 M KCl, 1 mM PMSF, 10 mg/ml each aprotinin and leupeptin) at 100 ml/1 Â 10 7 cells. The suspension was incubated at 41C for 1 h, and was resuspended at 15-min intervals. Extracts were then centrifuged at 14 000 rpm in a microfuge at 41C, and supernatants transferred to fresh tubes. To detect PML/RARa, 10 ml of nuclear extracts (approximately 1 Â 10 6 cells) was added to 10 ml 2 Â sample buffer and run on a 10% SDS-polyacrylamide gel. Proteins were transferred to nitrocellulose membranes (Bio-Rad, Mississauga, Ontario, Canada), stained with 0.1% Ponceau S (in 5% acetic acid) to ensure equal protein loading, and blocked with 25% fetal bovine serum in PBS containing 0.5% Triton X-100 for 1 h at room temperature. The membrane was then hybridized overnight at 41C with an antibody against RARa F domain (provided by Dr P Chambon). Following 3 Â 15-min washes with PBS containing 0.5% Triton X-100, PML/RARa was visualized by hybridization with 125 I-labelled protein A and subsequent autoradiography.
Sulforhodamine B assay
Cells were seeded at 1 Â 10 3 cells/well/0.1 ml in 96-well plates. Where required, 100 mM ZnSO 4 was added 24 h after seeding to allow for induction of PML/RARa expression. Cells were cultured overnight in the absence of As 2 O 3 , then treated with concentrations ranging from 5 nM to 100 mM. Following a 96-h treatment, cells were pelleted by centrifugation, fixed with 50% TCA, washed, and stained with sulforhodamine B. Protein staining was then measured spectrophotometrically at 630 nm.
Gel retardation and supershift assays
Cells (5 Â 10 6 ) were treated with 1 mM As 2 O 3 or 1 mM tRA for 24 h. Nuclear extracts were prepared and the gel retardation assay performed as previously described using a radiolabelled oligo corresponding to the RARb promoter's DR5. 6 Supershifts were performed with an anti-RARa antibody directed against the RARa F domain, kindly donated by Dr Pierre Chambon, as described previously. 6 
GSH assay
Intracellular reduced GSH levels were assessed enzymatically with glutathione reductase. Cells (1 Â 10 7 ) were harvested, washed, and lysed in 0.9 ml of 100 mM Tris-Cl by freeze-thaw cycling. Cell lysates were centrifuged and the supernatants transferred to Eppendorf tubes containing 0.1 ml of 30% Ssulfosalicyclic acid. Following an incubation of 15 min on ice, cell extracts were centrifuged for 2 min at 12 000 rpm and the supernatants transferred once again to new tubes. GSH levels per 100 ml sample were then measured spectrophotometrically by conversion of 5,5 0 -dithio-bis (2-nitrobenzoic acid) to its colored product upon reduction by GSH-dependent glutathione reductase, and expressed as nmol GSH/mg protein. Protein concentration was assessed through the Bio-rad protein assay (Bio-Rad).
Annexin-V staining
NB4 cells (4 Â 10 5 ) were seeded at 2 Â 10 5 cells/ml and treated for 48 h with 1 mM As 2 O 3 , alone or in combination with 100 mM buthionine sulfoximine (BSO). Cells were pelleted and washed once with cold PBS, then resuspended at 1 Â 10 6 cells/ml in 500 ml of 1 Â binding buffer (PharMingen, Mississauga, Ontario, Canada), and kept on ice. A measure of 5 ml of 1 Â annexin V-FITC solution (PharMingen) and 5 ml propidium iodide (at 0.25 mg/ml in binding buffer) were added to the cells, which were then incubated in the dark for 10 min on ice. Annexin-V positivity was assessed by flow cytometry with a Coulter flow cytometer.
TUNEL assay
Genomic DNA strand breaks characteristic of apoptosis were labelled in situ by terminal deoxynucleotidyl transferase (TdT) using an in situ cell death detection kit (Boehringer Mannheim, Laval, Quebec, Canada) according to the manufacturer's instructions. Briefly, cytospins containing 100 000 cells were fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100 and 0.1% sodium citrate. The cells were then exposed to the TUNEL reaction mixture containing TdT enzyme and fluorescein-labelled nucleotides, washed, and photographed under a fluorescence microscope. Our lab and others have previously documented the induction of apoptosis in the APL cell line, NB4, upon treatment with arsenic. In this report, we investigated the induction of apoptosis by As 2 O 3 in other hematologic cell lines, as well as NB4 subclones selected for resistance to arsenic. As Figure 1a illustrates, NB4 cells were more sensitive to arsenic than any other cell line examined, including the two non-APL myeloid leukemic cell lines, PLB-985 and U937, shown in Figure 1 . As illustrated, 2 mM As 2 O 3 leads to 100% cell death in NB4 cells, while both PLB-985 and U937 cell numbers continued to increase after 7 days of treatment with as much as 2 mM As 2 O 3 .
DCFH-DA staining for ROS detection
APL cells are potentially more sensitive to arsenic because of its unique expression of the PML/RARa oncoprotein. To examine the contribution of PML/RARa expression to As 2 O 3 -induced growth inhibition, we employed the sulforhodamine B assay to determine the sensitivity of non-APL, myeloid leukemic U937 cells to As 2 O 3 with and without the expression of exogenous PML/RARa. This assay allows for the approximation of IC 50 values by examining the growth inhibition of cells in response to a given drug at concentrations ranging over several logs. U937-PR9 cells stably expressing the fusion protein under the control of a zinc-inducible promoter and mock-transfected U937-SN4 cells were seeded at 1 Â 10 3 cells/well in 96-well plates, and PML/RARa expression was induced by treatment with 100 mM ZnSO 4 for 24 h. Treatment with ZnSO 4 did not affect the IC 50 value for arsenic in control, mock-transfected SN4 cells (data not shown). Induction of PML/RARa expression in PR9 cells was verified through Western blotting, and the levels of expression of this protein were found to be comparable to that in NB4 cells (Figure 1b) . To examine the effect of PML/ RARa expression over a large range of doses of arsenic, cells were then treated with As 2 O 3 , at concentrations ranging from 5 nM to 100 mM, for 4 days. The small leftward shift of the toxicity curve for zinc-treated cells shown in Figure 1c suggests an increase in the sensitivity of cells expressing PML/RARa. However, statistical analysis revealed this effect to be insignificant. Furthermore, as Figure 1d shows, induction of PML/RARa expression did not increase sensitivity to arsenic, as both U937-PR9 and mock-transfected U937-SN4 cells were equally growth inhibited by combined treatment with 1 mM As 2 O 3 and zinc. This result confirms that the enhanced effect of arsenic and zinc treatment is because of their combined toxicity, rather than PML/RARa expression. The result of this experiment therefore demonstrates the inability of PML/RARa expression to enhance arsenic sensitivity of at least this one non-APL cell line.
PML/RARa regulation does not mediate arsenic's growth inhibitory effects
Just as we and others have previously used retinoid-resistant subclones of the APL cell line, NB4, to investigate mechanisms of response to RA, we developed arsenic-resistant subclones to address the question of how arsenic exert its effects. [30] [31] [32] [33] These cells were generated by constant culture in the presence of As 2 O 3 at concentrations that were slowly increased over time. Once a population of cells was obtained that could be sustained in 1 mM As 2 O 3 , single clones were selected by plating in methylcellulose. The two clones that were selected for further expansion, NB4-M-AsR2 and NB4-M-AsR3, are now routinely cultured in the presence of 2 mM As 2 O 3 . As Figure 2a illustrates, NB4-M-AsR3 cells are approximately 10-fold less sensitive to As 2 O 3 than their parental cell line, NB4. Similar results were obtained with NB4-M-AsR2 cells (data not shown).
We have previously published the finding that arsenic induces degradation of the PML/RARa fusion protein in NB4 cells. 11 To determine whether a loss of this downregulation contributes to the resistance of NB4-M-AsR2 and NB4-M-AsR3 cells to arsenic, we performed a Western blot to determine the expression level of PML/RARa in both arsenic-resistant and -sensitive NB4 cells. In resistant cells routinely cultured in the presence of 2 mM As 2 O 3 , PML/RARa levels were approximately equivalent to those of NB4 cells following a 24-h treatment with arsenic (compare lanes 3 and 4 with lane 2). This downregulation was reversed in NB4-M-AsR2 cells grown for 1 month in the absence of arsenic, although these cells retained their ability to degrade the fusion protein when rechallenged with 1 mM As 2 O 3 for 24 h (Figure 2b, lanes 5 and 6) . Similar results were obtained with NB4-M-AsR3 cells, although their PML/RARa levels were not significantly elevated after removal of arsenic from the culture medium. Nevertheless, these cells displayed a further downregulation of the fusion protein upon arsenic retreatment (Figure 2b, lanes 7 and 8) .
We also performed an electrophoretic mobility shift assay to examine whether PML/RARa-DNA binding is lost in these cells, as it is in NB4 cells, upon treatment with As 2 O 3 . As previously demonstrated for RA, the disappearance of a RARE-binding band corresponds to the loss of binding by PML/RARa-RXR heterodimers because of degradation of the fusion protein. 6 Since PML/RARa is known to be degraded by arsenic, and degradation of PML/RARa because of RA treatment can be illustrated through loss of a specific DNA-binding band, we reasoned that the loss of a RARE-binding complex following arsenic treatment could be attributed to degradation of the fusion protein. Therefore, we performed an EMSA with nuclear extracts from NB4, the RA-resistant NB4 subclone NB4-MR4, NB4-M-AsR2, and NB4-M-AsR3 cells treated for 24 h with 1 mM RA or 1 mM As 2 O 3 . As Figure 2c illustrates, both RA and arsenic treatment induce the loss of a high molecular weight band in NB4, NB4-M-AsR2, and AsR3 cells. In NB4-MR4 cells, however, this band persists upon treatment with RA, disappearing only following treatment with As 2 O 3 . This result is in keeping with our published observations that PML/RARa is downregulated by arsenic, and not RA, in this cell line.
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The specificity of the band was verified through supershift analysis with an anti-RARa antibody, which resulted in two shifted bands corresponding to the RARa-RXR and PML/RARa-RXR complexes (open and solid arrowheads, respectively). Therefore, despite their resistance to the growth-inhibitory effects of arsenic, NB4-M-AsR2 and NB4-M-AsR3 cells respond as wild-type NB4 cells do in downregulating the fusion oncoprotein. These results further suggest that the sensitivity of APL cells to As 2 O 3 is not due to the expression and regulation of PML/RARa, but due to their intracellular biochemical environment.
Baseline GSH levels alone cannot predict tolerance or sensitivity to arsenic, although upregulation of GSH may be a mechanism for resistance in As 2 O 3 -resistant NB4 cells
To determine whether low GSH content could explain the unique sensitivity of APL cells to heavy metals, we assessed baseline GSH levels in several cell types and correlated these with their IC 50 values for a 4-day treatment with As 2 O 3 . While we found no correlation between baseline GSH and inherent sensitivity or tolerance to metals among cells of different types (Figure 3a) , we did find that GSH levels were elevated in the arsenic-resistant cell lines, NB3-M-AsR2 and NB4-M-AsR3 (Figure 3b) over that of NB4.
Dose-dependent GSH depletion by BSO correlates with response of NB4 cells to As 2 O 3
In order to determine whether a lowering of intracellular GSH content could render arsenic-resistant cells sensitive to arsenic, we cotreated NB4-M-AsR3 cells with As 2 O 3 and the GSHdepleting agent BSO. As Figure 4a shows, GSH depletion by nontoxic doses of BSO could completely restore sensitivity to arsenic upon NB4-M-AsR3 cells. In order to confirm that sensitization to heavy metals by BSO results from GSH depletion, we correlated the dose-dependent suppression of GSH levels in NB4 cells with the growth inhibitory effect by BSO plus As 2 O 3 . Figure 4b shows a clear relation between BSO concentration and the degree of GSH depletion following a 3-day treatment with doses ranging from 0.1 to 10 mM. This dose-dependent depletion of GSH directly correlated with the degree of sensitisation conferred by BSO, as shown in Figure 4c . This result strongly suggests that the depletion of GSH is, in fact, the BSO-mediated event responsible for sensitizing NB4 and other cells to arsenic.
GSH depletion synergizes with arsenic in the induction of apoptosis
We have previously reported the induction of apoptosis by As 2 O 3 in NB4 cells. In this study, we employed two assays to determine whether the synergy between BSO and arsenic was mediated by a synergistic induction of programmed cell death. Evidence for the induction of apoptosis was obtained through annexin-V staining of arsenic-treated NB4 cells, with or without BSO. Here we found that a 24-h treatment with 1 mM As 2 O 3 and 100 mM BSO significantly increased the number of apoptotic annexin-Vstaining cells, as compared to either the arsenic or BSO-treated groups alone (Figure 5a ). We also investigated the induction of apoptosis in an AML cell line much less sensitive to arsenic than NB4 in order to determine whether an inherently tolerant cell line, PLB-985 (see Figure 1a) , could be sensitized to As 2 O 3 upon GSH depletion. TUNEL analysis, shown in Figure 5b , was performed to confirm that arsenic and BSO synergize in the induction of apoptosis in these cells, as shown for the more sensitive NB4 cell line. Here a 48-h treatment with 1 mM As 2 O 3 caused only a slight increase in the number of apoptotic cells over the untreated control group. Cotreatment with 25 mM BSO, however, sensitized the cells such that a 1 mM treatment induced a response similar to that induced by 10 mM As 2 O 3 alone (data not shown), corresponding to a roughly 10-fold sensitization by BSO.
GSH depletion increases arsenic-induced ROS formation in NB4 cells, and restores ROS formation in arsenic-resistant NB4-M-AsR3 cells
Since one role of GSH is the squelching of free radicals, we examined whether GSH depletion could potentiate the accumulation of ROS following arsenic treatment in arsenic-resistant and -sensitive APL cells. As shown in Figure 6a , a 5 h treatment with 1 mM As 2 O 3 generated ROS in 8.1% of NB4 cells, as compared to 1.8% of cells treated with vehicle alone. In contrast, an identical treatment induced no ROS formation in NB4-M-AsR3 cells (Figure 6b) , with only 1.0% positive cells in the treated group and 1.1% for untreated cells. An overnight pretreatment with 100 mM BSO further increased the number of positive cells to 11.9% in NB4 (Figure 6a) . Interestingly, BSO pretreatment also restored this arsenic-induced generation of ROS in NB4-M-AsR3 cells, and increased ROS-positive cells to 7.9% (Figure 6b ). These results suggest that one mechanism of synergy between As 2 O 3 and BSO may be in the induction of free radicals. Furthermore, treatment with BSO can reverse arsenic resistance by depletion of GSH, and thereby effectively overcome the mechanism of resistance in these cells.
Discussion
As 2 O 3 is an effective therapy against one hematologic malignancy, acute promyelocytic leukemia (APL), which is known to be uniquely responsive, in vitro and in vivo, to RA. To date, however, arsenic has been less effective in vitro against other cancer cells.
13,34 Therefore, we examined determinants of sensitivity to arsenic in APL cells, and mechanisms by which to enhance response to this agent in arsenic-resistant APL and non-APL leukemias.
Although the PML/RARa fusion oncoprotein is characteristic and necessary for the development of APL, and both RA and As 2 O 3 induce its degradation, [10] [11] [12] we present evidence suggesting that PML/RARa is not principally responsible for the : 1µM tRA sensitivity of APL cells to arsenic. We found that exogenous expression of this protein could not confer sensitivity to arsenic upon the non-APL leukemic cell line U937. The U937-PR9 cell line, stably transfected with a zinc-inducible PML/RARa expression vector, allowed us to measure how PML/RARa expression influences arsenic response without complicating the analysis by comparing cell lines having multiple potential differences. That expression of the fusion protein did not significantly change the sensitivity of these cells to arsenic is consistent with reports from our lab and others showing that an RA-resistant NB4 subclone, NB4.306, is as sensitive to arsenic as its parental cell line. 35 Although harboring the t(15;17) translocation and expressing PML/RARa mRNA, expression of PML/RARa protein in this cell line has not been reported. Furthermore, we present evidence that PML/RARa is downregulated by arsenic in both arsenic-resistant and -sensitive NB4 cells, as determined both by Western blotting and electrophoretic mobility shift assays. The latter assay revealed normal RARa-and PML/RARa-binding to retinoid-responsive DNA elements in both arsenic-resistant cell lines, with regulation by RA and arsenic mirroring that of wild-type NB4. This result is consistent with that obtained with another NB4 subline derived by Gianni et al 36 for arsenic resistance, in which PML/RARa is also degraded by As 2 O 3 without induction of apoptosis. Thus, expression of the fusion protein and its subsequent regulation by arsenic may not explain the sensitivity of APL cells to this agent.
The fact that PML/RARa expression did not confer sensitivity to arsenic is perhaps not surprising, given its documented role as an inhibitor of apoptosis. Nason-Burchenal et al 37 revealed an antiapoptotic function for PML/RARa by inhibiting its expression with the use of a hammerhead ribozyme. Treatment of APL cells with a catalytic ribozyme inhibited PML/RARa expression and had a positive effect on cell growth alone, while a noncatalytic control ribozyme had no effect. 37 PML/RARa expression has been correlated with resistance to known inducers of apoptosis, including Fas ligand, tumor necrosis factor (TNF), and interferon (IFN), following its expression in hematopoietic progenitor cells. 38 Similarly, exogenous, zinc-induced expression of PML/ RARa in U937 cells, the same model used in Figure 1 of this manuscript, rendered these cells resistant to TNF-induced apoptosis. 39 Furthermore, our own experiments with the chemotherapeutic drug, doxorubicin, revealed no change in sensitivity of U937 cells expressing PML/RARa to this drug relative to their nonexpressing parental control cells (data not shown). Together, these results imply that PML/RARa expression confers protection from a number of apoptotic inducers, and further supports our finding that its expression is not a determinant of sensitivity of APL cells to arsenic.
One instance where PML/RARa expression likely does contribute to a therapeutic response by arsenic is in combination with tRA for the treatment of RA-resistant APL. We recently reported a synergistic differentiation effect of arsenic and tRA in two RA-resistant APL cell lines NB4-MR2 and NB4-MR4. 40 In these cells, loss of expression of the fusion protein by subapoptotic doses of arsenic relieves the block to differentiation, and primes the cells for differentiation by RA. The effects of combined arsenic and RA treatment on the growth of wild-type, RA-responsive APL cells are more highly disputed, however. Our lab and others have reported that arsenic inhibits RA-induced gene expression and differentiation of NB4 and freshly isolated patient cells in vitro. 11 Conversely, in vivo studies with transgenic mice engineered to express PML/ RARa have shown an increased mean survival time with combined arsenic and RA treatment over those treated with either agent alone. 41 Clearly, work remains to be done to resolve the role for combined arsenic and RA therapy in the treatment of APL.
The data presented here, as well as in other recent reports, suggest that the unique sensitivity of APL cells may result from their biochemical or cellular background. This leads to our hypothesis that modulation of the biochemical environment of the cell might increase the efficacy of arsenic against less responsive, non-APL malignancies. An alternative explanation for the unique sensitivity of APL cells is their low GSH content, as compared to that of other hematological malignancies. GSH confers protection against xenobiotics and several chemotherapeutic agents, including alkylating agents and cisplatin, and plays a major role in maintaining intracellular redox potential. [42] [43] [44] A recent report described a direct relation between GSH levels and arsenic tolerance in three distinct AML cell lines. 13 Consistent with this hypothesis is our finding that two arsenic-resistant subclones of NB4 had higher baseline GSH levels than their parental cell line. However, we found that nonleukemic malignant cells did not consistently show a correlation between arsenic sensitivity and GSH content (Figure 3 ). This suggests that steady-state GSH content may be only one factor dictating cellular resistance or sensitivity to heavy metals. The ability to synthesize GSH may be an additional factor in determining tolerance to arsenic, suggesting an important role for the enzymes in the biosynthetic pathway of GSH. Also, the expression level of other proteins, including GSH utilizing enzymes (including GSTs) and those involved in metal ion chelating (metallothionein), free radical scavenging and peroxide metabolism (GSH peroxidase, catalase) may play important roles. Since arsenic is exported from the cell in an ATPdependent manner by the multidrug-resistance-associated protein (MRP), high expression of this membrane pump could also cause metal resistance. 43 Each of these proteins has been shown to be inducible by arsenic, or overexpressed in some arsenicresistant cell systems, 16, 45, 46 and their relative abundance may exert a combined effect on the response to As 2 O 3 . While neither GSTp, MRP, nor GPx were found to be overexpressed in NB4-M-AsR2 and NB4-M-AsR3 cells (data not shown), both resistant cell lines, and all cancer cells tested, regardless of GSH content or their initial response to As 2 O 3 , could be sensitized by intracellular GSH depletion. Interestingly, GSH depletion had little effect upon the sensitivity of a number of cell lines to a second heavy metal antineoplastic agent, 4, 9-dimethyl 1,10-phenanthroline bisperoxo-oxovanadium (data not shown), suggesting that this effect may be specific to a subset of metals.
Combined arsenic and GST depletion may prove useful in the face of acquired arsenic resistance. Our in vitro experiments demonstrate that at least one mechanism of arsenic resistance may be an upregulated GSH content, and in fact, some evidence suggests that malignant cells often have significantly elevated GST levels. 47 Our NB4 arsenic-resistant cell lines are roughly 10 times more resistant to As 2 O 3 than their parental cells. We have previously shown that a mechanism of RA resistance derived in vitro in the NB4 APL cell line predicted mechanisms of patient-derived resistance. [30] [31] [32] [33] We hypothesize that this in vitro mechanism of arsenic resistance may similarly parallel in vivo arsenic failure. Upon treatment with BSO, however, both NB4-M-AsR2 and NB4-M-AsR3 cells (Figure 4a and data not shown) were restored to the sensitive phenotype, so that under conditions of GSH depletion, they were as sensitive as NB4 cells treated in the same manner. These results confirm our hypothesis that GSH levels are an important factor in determining cellular response to arsenic, although they alone cannot predict the sensitivity of all tumor cells to As 2 O 3 .
One likely consequence of upregulated GSH content is protection against ROS and free radical generation. Since arsenic has been shown to induce apoptosis through an H 2 O 2 -dependent pathway, and to induce ROS formation in NB4 cells, we examined the effects of GSH depletion on arsenic-induced ROS formation in NB4 and NB4-M-AsR3 cells. We found that GSH depletion, a condition that strongly promotes arsenic-induced apoptosis, also enhanced arsenic-induced ROS formation in NB4 cells ( Figure 6 ). Furthermore, GSH depletion was a requirement for both arsenic-induced apoptosis and ROS accumulation in NB4-M-AsR3 cells ( Figure 6 ). Consistent with these results, pretreatment with the known antioxidant, N-acetylcysteine (NAC), prevented arsenic-induced apoptosis (data not shown), supporting a role for free radical formation in mediating arsenic's effects. Taken together, these results suggest that combined arsenic and BSO treatment may be useful against cancers tolerant to arsenic, as well as against cancers with derived resistance to arsenic alone.
The use of GSH-depleting agents to increase therapeutic response to chemotherapy has some precedent. In a Phase I clinical trial, O'Dwyer et al 48 reported clinical responses upon treatment with BSO and melphalan in two patients with recurrent cancers. Importantly, this study demonstrated tumor GSH depletion by BSO without an increase in myelosuppression upon melphalan treatment. The evidence that GSH depletion and treatment with alkylating agents can be safely tolerated by human patients, together with our in vitro data, suggests that combining GSH depletion and arsenic treatment may provide an improved therapeutic index, especially in those non-APL malignancies where arsenic alone is not effective.
